Veru Dirección

Dirección controles de criterios 3/4

Veru's El consejero delegado es Mitch Steiner , nombrado en Oct 2016, tiene un mandato de 7.17 años. la remuneración anual total es $6.10M , compuesta por 12.5% salario y 87.5% primas, incluidas acciones y opciones de la empresa. posee directamente 8.17% de las acciones de la empresa, por valor de $6.36M . La antigüedad media del equipo directivo y del consejo de administración es de 5.3 años y 4.5 años respectivamente.

Información clave

Mitch Steiner

Chief Executive Officer (CEO)

US$4.7m

Compensación total

Porcentaje del salario del CEO	18.4%
Permanencia del CEO	7.5yrs
Participación del CEO	5.0%
Permanencia media de la dirección	5.6yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Aug 03

Veru eligible for expedited review in U.K. for COVID-19 therapy

Jul 25

Veru: The Signs Seem To Point To An EUA For Sabizabulin

Jul 13

Veru phase 3 results of sabizabulin for COVID-19 published in NEJM

Jul 06

Veru: On Right Track For FDA EUA Submission

May 27

Is Veru (NASDAQ:VERU) Using Debt Sensibly?

May 25

Veru: Where Big Pharma Failed To Tread

May 17

Veru: The Russian/Ukraine Conflict May Pose Challenges

Mar 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mitch Steiner en comparación con los beneficios de Veru?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$63m
Sep 30 2023	US$5m	US$866k	-US$93m
Jun 30 2023	n/a	n/a	-US$125m
Mar 31 2023	n/a	n/a	-US$141m
Dec 31 2022	n/a	n/a	-US$116m
Sep 30 2022	US$6m	US$761k	-US$84m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	n/a	n/a	-US$16m
Sep 30 2021	US$2m	US$618k	US$7m
Jun 30 2021	n/a	n/a	-US$144k
Mar 31 2021	n/a	n/a	-US$476k
Dec 31 2020	n/a	n/a	US$2m
Sep 30 2020	US$1m	US$502k	-US$19m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	n/a	n/a	-US$13m
Sep 30 2019	US$800k	US$392k	-US$12m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$22m
Dec 31 2018	n/a	n/a	-US$22m
Sep 30 2018	US$740k	US$383k	-US$24m
Jun 30 2018	n/a	n/a	-US$21m
Mar 31 2018	n/a	n/a	-US$14m
Dec 31 2017	n/a	n/a	-US$11m
Sep 30 2017	US$831k	US$406k	-US$9m

Compensación vs. Mercado: Mitch($USD6.10M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Mitch ha sido consistente con los resultados de la empresa en el último año.

CEO

Mitch Steiner (62 yo)

7.5yrs

Permanencia

US$4,714,041

Compensación

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mitchell Steiner	Chairman	7.5yrs	US$4.71m	5.01% $ 9.1m
Harry Fisch	Vice Chairman & Chief Corporate Officer	7.5yrs	sin datos	5.47% $ 9.9m
Michele Greco	CFO & Chief Administrative Officer	6.3yrs	US$1.55m	0.066% $ 119.3k
K. Barnette	Chief Scientific Officer	5.6yrs	US$1.69m	0% $ 0
Samuel Fisch	Executive Director of Investor Relations & Corporate Communications	5yrs	sin datos	sin datos
Michael Purvis	Executive VP	3.1yrs	sin datos	sin datos
Kevin Gilbert	Executive Vice President of Corporate Development	7.3yrs	sin datos	sin datos
Martin Tayler	Executive Vice President of FC2 Global Operations	no data	US$193.01k	sin datos
Philip Greenberg	Executive VP & Deputy General Counsel	3.3yrs	sin datos	sin datos
Domingo Rodriguez	Executive Vice President of Global Clinical Operations	6yrs	sin datos	sin datos
Gary Bird	Executive Vice President of Quality & Regulatory Affairs	5.2yrs	sin datos	sin datos
Jason Davies	Executive VP and GM of UK	1.7yrs	sin datos	sin datos

5.6yrs

Permanencia media

61.5yo

Promedio de edad

Equipo directivo experimentado: VERUEl equipo directivo de la empresa es veterano y experimentado (5.3 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mitchell Steiner	Chairman	7.5yrs	US$4.71m	5.01% $ 9.1m
Harry Fisch	Vice Chairman & Chief Corporate Officer	7.5yrs	sin datos	5.47% $ 9.9m
Louis Aronne	Chief Medical Advisor & Member of the Scientific Advisory	less than a year	sin datos	sin datos
David D. Ho	Chairman of Scientific Advisory Board	1.3yrs	sin datos	sin datos
Andrew Love	Board Observer	7.5yrs	sin datos	sin datos
Robert Schooley	Member of the Scientific Advisory Board	less than a year	sin datos	sin datos
Michael Rankowitz	Independent Director	6.1yrs	US$875.93k	0.068% $ 124.0k
Xiaoqin Lu	Independent Director	2.9yrs	US$835.75k	0.0067% $ 12.1k
Caroline Apovian	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Mario Eisenberger	Independent Director	7.5yrs	US$795.57k	0% $ 0
Grace Hyun	Independent Director	3.7yrs	US$755.39k	0.010% $ 18.3k
Erik Swenson	Member of the Scientific Advisory Board	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de VERU se considera experimentada (4.5 años de antigüedad promedio).

Veru Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc., Annual General Meeting, Mar 26, 2024

High number of new and inexperienced directors

Veru Announces Executive Appointments

Veru Inc., Annual General Meeting, Mar 28, 2023

Recent updates

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Consensus revenue estimates decrease by 32%, EPS upgraded

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

Consensus revenue estimates decrease by 44%, EPS upgraded

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Consensus revenue estimates increase by 12%

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Consensus revenue estimates fall by 60%

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$25.60

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Price target decreased to US$25.60

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed

Veru: A Good Combination Of A Stable Business And Growth Opportunities

Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy

Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific

Consensus revenue estimates fall by 25%

Independent Director exercised options and sold US$1.8m worth of stock

Veru sheds 13% to end rally as director sells shares

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Veru Q3 2022 Earnings Preview

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022

Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc

Veru eligible for expedited review in U.K. for COVID-19 therapy

Veru: The Signs Seem To Point To An EUA For Sabizabulin

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients

Veru phase 3 results of sabizabulin for COVID-19 published in NEJM

Veru Submits Emergency Use Authorization Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients At High Risk for ARDS